Pfizer has announced that clinical trials into its CCR5 inhibitor maraviroc are to continue without any change in their design or structure.
Last month GlaxoSmithKline (GSK) announced that it was terminating a phase II B study involving its CCR5 inhibitor aplaviroc (GW873140) in treatment-naïve patients after unexpectedly high levels of liver toxicity were identified
The independent Data Safety and Monitoring Board for maraviroc met twice in the summer of 2005 and reviewed phase III and phase II B trial data on the drug’s safety. These reviews included a consideration of maraviroc’s hepatic safety. The Data Safety and Monitoring Board decided that it was safe to continue with both the phase III and phase II B studies in treatment-experienced and treatment-naive individuals.